<DOC>
	<DOCNO>NCT00368719</DOCNO>
	<brief_summary>To assess long-term safety tacrolimus ointment</brief_summary>
	<brief_title>Evaluation Assess Long Term Safety Tacrolimus Ointment Atopic Dermatitis</brief_title>
	<detailed_description>To assess long-term safety tacrolimus ointment 0.03 % 0.1 % treatment subject atopic dermatitis actual use condition , include risk develop cutaneous systemic malignancy . The FDA EMEA approve Tacrolimus ointment , 0.03 % child 0.1 % 0.03 % adult , treatment atopic dermatitis . As part approval process , FDA EMEA request post-marketing commitment regard safety long-term use Tacrolimus ointment pediatric atopic dermatitis subject .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subject has/had atopic dermatitis . Subject applied tacrolimus ointment 0.03 % 0.1 % least 6 week , continuously intermittently . This may include subject enrol previous tacrolimus ointment study and/or subject commercial product exposure prior study enrollment . Subject age first tacrolimus ointment exposure is/was &lt; 16 year age . Subject/Caregiver give write informed consent assent require state and/or governmental law , include access relevant clinical medication data , storage analysis data . Subject/Caregiver agree comply program requirement include annual physical exam biennial dermatological exam agree contact provide information describe document Primary Investigator Dr. Lamb Covance Periapproval Services , Inc . Subjects have/ Atopic Dermatitis . Subjects must use Tacrolimus ointment prior age 16 .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>